On November 6, Medline Inc. fell 3.05% in Regular Trading, trading near $39.08 per share, with turnover of $203 million.

The clearest recent catalyst in the market was an event-driven update: UBS raised its price target on Medline Inc. to $49 from $43 and maintained a Buy rating, but the shares still pulled back after the earlier earnings-driven rally.

Earlier, the company reported quarterly adjusted EPS of $0.44, above the $0.35 consensus estimate, and revenue of $7.856 billion, above the expected $7.723 billion. Net sales also increased from $7.12 billion a year earlier to $7.86 billion. The recent decline appears to reflect a near-term retracement after the post-earnings advance rather than a deterioration in the latest reported fundamentals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)